STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

(CIN: L46900MH1942PLC003556)

Date: November 05, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365 **ISIN: INE320M01019**

Subject: Outcome of Board Meeting held on November 05, 2026.

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Thursday, November 05, 2026 at the Registered Office of the Company, inter alia, have considered and approved Un-Audited Standalone Financial Results of the Company for the second quarter ended September 30, 2026.

In this regards, we are enclosing herewith :

1. Un-Audited Standalone Financial Results of the Company for the second quarter ended September 30, 2026, along with Limited Review Report thereon.
2. Statement of Assets & Liabilities and Cash Flow as on September 30, 2026 (Standalone).
3. Non-Applicability of Regulation 23(9) of SEBI (LODR) (Amendments) Regulation, 2018
4. Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid information will also be made available on website of the company.

The meeting commenced at **01:45 PM** and concluded at **02:15 PM.**

The same may please be taken on record.
Thanking You.
Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)

Mehta Ruchit P.

RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India
Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad– 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

Independent Auditor Review Report on Unaudited Standalone Financial Results for the quarter ended 30th September 2026, of STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED) pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.

To,
The Board of Directors,
STARSOURCE MULTITRADE LIMITED
(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

1. We have reviewed the accompanying statements of unaudited IND-AS Financial Results of **STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)** ('the Company") for the quarter ended 30th September, 2026 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").

2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Director's, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Listing Obligations. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion in this quarter.

Basis for Qualified Conclusion:

During the course of our review, information available from the GST Portal the assessee is engage in wholesale and distribution (general trader) and as per that the same is inactive w.e.f. 29th May 2026. The Company is licensed/registered for wholesale and distribution activities as a General Trader Accordingly, the Company is not in compliance with filing of proper return. Management, however, represented that the Company was not registered under the Goods and

SSRV & ASSOCIATES
VISHNUKANT KABRA
MEMB No. 403437
MUMBAI CHARTERED ACCOUNTANTS

Services Tax laws and, accordingly, did not provide GST registration details, or other GST records for the period under review.

4. Based on our review conducted as stated above, except for the possible effects of the matter described in the Basis for Qualified Conclusion paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S S R V & Associates
Chartered Accountants
Firm Reg. No.: 135901W



Vishnu Kant Kabra
Partner
M. No.: 403437
Place: Mumbai
Date: 5th November, 2026
UDIN: 26403437JBALCF6309

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

CIN: L46900MH1942PLC003556

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India

Statement of audited Standalone Financial Results for the Quarter ended September 30, 2026

(Rs. In Thousands)

	Particulars	Quarter Ended			Half year ended		For The Year Ended
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
A	**Date of start of reporting period**	01-07-2026	01-04-2026	01-07-2025	01-04-2026	01-04-2025	01-04-2025
B	**Date of end of reporting period**	30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
C	**Whether results are audited or unaudited**	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Income**						
	(a) Revenue From Operations	-	745.85	5,256.56	745.85	5,256.56	5,256.56
	(b) Other Income	-		-	-	207.12	238.86
	Total Income	**-**	**745.85**	**5,256.56**	**745.85**	**5,463.68**	**5,495.42**
2	**Expenditure**				-		
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	3,765.35	-	3,765.35	3,765.35
	(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefit expense	178.50	288.00	216.00	466.50	456.60	888.60
	(e) Finance Costs	1.75	0.31	0.59	2.06	5.97	9.81
	(e) Depreciation and amortisation expense	1.35	1.35	-	2.70	-	3.48
	(f) Other Expenses	440.66	246.35	294.48	687.01	1,18,306.27	1,19,377.10
	Total expenses	**622.27**	**536.01**	**4,276.43**	**1,158.28**	**1,22,534.19**	**1,24,044.34**
	Profit (loss) Before exceptional & Extraordinary items and Tax	**(622.27)**	**209.84**	**980.14**	**(412.43)**	**(1,17,070.51)**	**(1,18,548.93)**
	Exceptional items	-	-	-	-	-	-
	Profit (loss) from ordinary activities before tax	**(622.27)**	**209.84**	**980.14**	**(412.43)**	**(1,17,070.51)**	**(1,18,548.93)**
	Tax Expenses - Current Tax	-	-	-	-	-	-
	(less):· MAT Credit	-	-	-	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
	Deferred Tax (Assets)/llabtlltles	-	-	-	-	-	0.80
	Profit (loss) from ordinary activities	**(622.27)**	**209.84**	**980.14**	**(412.43)**	**(1,17,070.51)**	**(1,18,549.73)**
	Other Comprehensive Income (OCI)						
	Items that will not be reclassified to profit or loss						
	Income tax relating to items that will not be reclassified to profit or	-	-	-	-	-	-
	Items that will be reclassified to profit or loss						
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Profit After Other Comprehensive Income	**(622.27)**	**209.84**	**980.14**	**(412.43)**	**(1,17,070.51)**	**(1,18,549.73)**
	Profit/(Loss) From Discountinuing Operation Before Tax						
	Tax Expenses of Discontinuing Operations						
	Net Profit/(Loss) from Discountinuing Opration After Tax	-	-	-	-	-	-
	Profit(Loss) For Period Before Minority Interest	-	-	-	-	-	-
	Share Of Profit / Loss Associates						
	Profit/Loss Of Minority Interset						
	Net Profit (+)/ Loss (-) For the Period	**(622.27)**	**209.84**	**980.14**	**(412.43)**	**(1,17,070.51)**	**(1,18,549.73)**
	Details of equity share capital						
	Paid-up equity share capital	15,000.00	15,000.00	15,000.00	15,000.00	15,000.00	15,000.00
	Face value of equity share capital (per share)	10.00	10.00	2,229.00		0.00	
	Reserve Excluding Revaluation Reserves As Par Balance sheet Of previous Year	(2,541.77)	(1,919.50)	(624.51)	(2,541.77)	(624.51)	(2,129.34)
	Earnings per share (EPS)						
	Basic earnings per share from countinuing And Discountinuing operations	(0.41)	0.14	0.65	(0.03)	(78.05)	(7.90)
	Diluted earnings per share from countinuing And Discountinuing operations	(0.41)	0.14	0.65	(0.03)	(78.05)	(7.90)

sr no.	Notes
1	The above said finanical results were reviewed by the Audit Committee and then approved by the Board of Directors of the company at their respective Meetings held on November 05, 2026. The statutory auditors of the Company have carried out limited review of the same.
2	The Statutory Auditors have carried out limited review of the Unaudited Results of the Compnay for the Quarter ended 30/09/2026.
3	These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time and considering going concern aussmption.
4	The Company has no reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.
5	The figures for the corresponding previous period have been regrouped/ reclassified wherever necessary, to make them comparable.

For,STARSOURCE MULTITRADE LIMITED



Mr.Ruchit Mehta
(Managing Director)
DIN : 08810586

Date : 05/11/2026
Place : Kalyan

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

CIN: L 4 6 9 0 0 M H 1 9 4 2 P L C 0 0 3 5 5 6

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India

Standalone Statement of Balance Sheet as at 30th September, 2026

(Rupees in Thousands)

Particulars	As at 30th September, 2026	As at 31st March, 2026
ASSETS		
Non-current assets		
(a) Property, plant and equipment	6.95	9.65
(b) Capital work-in-progress		-
(c) Investment in properties	60.75	60.75
(d) Financial assets		-
(i) Investments		
(ii) Trade receivables		
(iii) Loan		-
(e) Deferred Tax Assets		
(f) Other non-current asset		-
Total non-current assets	**67.71**	**70.40**
Current assets		
(a) Inventories		
(b) Financial assets		
(i) Trade receivables	4,884.39	4,884.39
(ii) Cash and cash equivalents		122.26
(iii) Other bank balance	57.02	
(iv) Loans & Advances	13,196.23	13,040.56
(v) Other financial asset		-
(vi) Deposites	62.00	
(c) Income/Current tax assets (net)		
(c) Other current assets		
Total current assets	**18,199.63**	**18,047.21**
TOTAL ASSETS	**18,267.34**	**18,117.62**
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	15,000.00	15,000.00
(b) Other equity	(2,515.93)	(2,103.50)
Total equity	**12,484.07**	**12,896.50**
Non-current liabilities		-
(a) Financial liabilities		-
(i) Borrowings		
(b) Defferred tax liability (net)	(87.08)	(87.08)
(c) Other non current liabilities	150.00	150.00
Total non current liabilities	**62.92**	**62.92**
Current liabilities		-
(a) Financial liabilities		
(i) Borrowings		-
(ii) Trade payable		
1. Dues of micro enterprises and small enterprises		-
2. Dues of creditor other than micro enterprises and small enterprises	4,506.19	4,778.19
(iii) Other financial liabilities		-
(b) Provision		300.00
(c) Income/Current tax liabilities (net)	80.00	80.00
(d) Other current liabilities	1,134.15	-
Total current liabilities	**5,720.34**	**5,158.19**
ES	**18,267.34**	**18,117.62**

STARSOURCE MULTITRADE LIMITED

For and on behalf of the board

Mehta Ruchit P.

Ruchit Mehta
Managing Director
DIN : 08810586

Date :- 05/11/2026
Place :- Kalyan

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

CIN: L 4 6 9 0 0 M H 1 9 4 2 P L C 0 0 3 5 5 6

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan,– 421301, India

Statement of Unaudited Standalone Cash Flow Statement for the half year ended September 30, 2026

	Particulars	As on 30th September, 2026	As on 31st March, 2026
		Rs. In Thousand	Rs. In Thousand
A.	**Cash flow from operating activities**		
	Profit before Tax	(412.43)	(1,18,549.73)
	Adjustments for:		
	Depreciation and amortisation	2.70	3.48
	Interest Income		
	Finance costs	2.06	
	Profit on Sale of Fix Asset	-	
	Reversal of expected credit loss	-	
	Compensation against Extinguishment of share		
	Compensation on sompulsory Acquisition and damages		
	Provision for doubtful trade receivable		-
	Operating profit / (loss) before working capital changes	(408)	(1,18,546)
	Movements in Working Capital		
	(Increase) / Decrease Inventories	-	0.00
	(Increase) / Decrease loans, advances & Deposites	(217.67)	(13,040.56)
	Increase / (Decrease) Trade payables	(272.00)	5,158.99
	(Increase) / Decrease Trade Receivables	0.01	(4,884.23)
	(Increase) / Decrease Other Non Current Assets		1,917.83
	Increase / (Decrease) Short Term Provisions	(300.00)	
	Increase / (Decrease) Other current Assets		
	Increase / (Decrease) Other Non current liabilities		25,081.00
	Increase / (Decrease) Other current liabilities	1,134.15	(1,902.17)
	Net Cash Generated/(Used in) Operations	344.49	12,330.86
	Cash flow from extraordinary items	-	-
	Direct Taxes Paid including for past years		-
	Dividend & Dividend Tax Paid	-	-
	Net cash flow from / (used in) operating activities (A)	(63.18)	(1,06,215.37)
B.	**Cash flow from Investing activities**		
	Interest received	-	
	Compensation against Extinguishment of share	-	
	Compensation on sompulsory Acquisition and damages	-	
	Purchase of Fixed Assets	-	
	Movement In Investments		(0.05)
	Sales of Equity Share	-	109.90
	sales of Property plant and equipment	-	
	Dividend Received	-	-
	Net cash flow from / (used in) investing activities (B)	-	109.85
C.	**Cash flow from financing activities**		
	Finance cost	(2.06)	
	Increase / (Decrease) Long Term Borrowings		
	Increase / (Decrease) Short Term Borrowings		
	Net cash flow from / (used in) financing activities (C)	(2.06)	-
	Net increase / (decrease) in Cash and cash equivalents (A+B+C)	**-65.26**	**-1,06,105.54**
	Cash and cash equivalents at the beginning of the year	122.27	1,06,227.80
	Cash and cash equivalents at the end of the year *	**57.01**	**122.27**
	*** Comprises:**		
	(a) Cash on hand		
	(b) Balances with banks		
	(i) In current accounts		
	(ii) In deposit accounts		
	Total	-	-

STARSOURCE MULTITRADE LIMITED

For and on behalf of the board

Mehta Ruchit P.

Ruchit Mehta
Managing Director
DIN : 08810586

Date :- 05/11/2026
Place :- Kalyan

STARSOURE MULTITRADE LIMITED
RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED
30TH SEPTEMBER, 2026

Rs. In Thousands

PARTICULARS	STANDALONE	
	UN-AUDITED QUARTER ENDED 30.09.2026	AUDITED YEAR ENDED 31.03.2026
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	**(622.27)**	**(412.97)**
Benefit / (Charge):		
Impact of Deferred Income (Government Grant) Amortized to Income	0.00	0.00
Impact of Fair Valuation of Financial Instruments	0.00	0.00
Impact of Actuarial Gain / Loss Taken OCI	0.00	0.00
Impact of Adjustment of Deferred Tax Income	0.00	0.00
Impact of Adjustment of MAT Credit Entitlement	0.00	0.00
Net Profit / (Loss) for the Period (as per AS)	**(622.27)**	**(412.97)**

For Starsource Multitrade Limited



Mehta Ruchit P.

RUCHIT MEHTA
MANAGING DIRECTOR
DIN: 08810586

Place : Kalyan
Date : 05/11/2026

OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) -
FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2026

(In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated December 31, 2024)

Sr. No	Particulars	Remarks
1	B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	NOT APPLICABLE
2	C. Format for disclosing outstanding default on loans and debt securities	NOT APPLICABLE
3	D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter)	NOT APPLICABLE
4	E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	NOT APPLICABLE

FOR STARSOURCE MULTITRADE LIMITED



Mehta Ruchit

Date : 05/11/2026
Place : Kalyan

RUCHIT MEHTA
MD & CEO
DIN: 08810586